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Abstract
Purpose of Review This article provides the current evidence
related to transcervical radiofrequency ablation of uterine fi-
broids under integrated intrauterine sonography guidance (the
Sonata System).
Recent Findings Published data on the treatment of fibroids
with the Sonata System has demonstrated significant median
reductions in total (73.3%) and perfused (73.3%) uterine fi-
broid volume, menstrual bleeding (72.3%), symptom severity
(62.5%), and improvements in health-related quality of life
(127%) at 12 months post-ablation. A clinical trial under an
FDA Investigational Device Exemption is in progress.
Summary The Sonata System is a promising treatment modal-
ity for uterine fibroids. As an incisionless, minimally invasive
treatment that does not require general anesthesia or hospital-
ization, it has the potential for redefining the current paradigm
for management of symptomatic fibroids.
Keywords Fibroids . Radiofrequency ablation . Sonata .
Intrauterine sonography
Introduction
Uterine fibroids (leiomyomata uteri) are benign solid tumors
that affect the majority of women in the USA by age 50 [1].
While often asymptomatic, fibroids can result in abnormal
uterine bleeding, pelvic pressure, subfertility, dyspareunia,
and other symptoms. Uterine fibroids are the leading indica-
tion for hysterectomy in the USA, Europe, and other countries
[2–4]. While treatment options (hysterectomy, myomectomy,
uterine artery embolization) exist, they typically involve major
surgery and inpatient admission, require incisions and general
anesthesia, and can be associated with significant adverse
events and prolong the return to the activities of daily living.
Hysteroscopic myomectomy is limited to smaller submucous
fibroids, with some requiring staggered treatment with multi-
ple partial resections to avoid inadvertent serosal injury along
with fluid overload and other complications [5].
A 2013 study indicated that nearly 80% of women
expressed an interest in minimally invasive options for
fibroid treatment and 51% reported a desire to conserve
their uteri; of particular note, 25% delayed treatment up to
5 years [6]. The situation is similar in Europe, as Downes
and colleagues found that nearly 33% of Italian women
with symptomatic fibroids, and almost a quarter of fibroid
patients in the UK, waited over 5 years before obtaining
treatment [4].
In response to the desire for novel, minimally invasive
solutions for women with fibroids who desire uterine conser-
vation, there has been a growing interest in the use of radio-
frequency (RF) energy to ablate uterine leiomyomata. The
successful application of RF ablation to solid tumors of the
liver and other organs has affirmed the validity of this ap-
proach [7–9].
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The Sonata® System (Gynesonics; Redwood City, CA),
previously known as VizAblate™, integrates radiofrequency
ablation for the treatment of fibroids with intrauterine sonog-
raphy for real-time imaging within a single medical device
[10]. It is CE-marked (Conformité Européene)in the
European Union and is currentlyunder investigation in the
USA. Because it is placed transcervically, it is incisionless
and does not require general anesthesia. In particular, Sonata
enables the outpatient treatment of a wide range of uterine
fibroid types. While Sonata can treat FIGO (Fédération
Internationale de Gynécologie et d'Obstétrique) type 1 and
type 2 fibroids, it can also ablate fibroids that are not treatable
with hysteroscopic methods (e.g., FIGO types 3, 4, 5, 6 and
types 2–5 [transmural]).
This paper will provide an overview of transcervical radio-
frequency ablation (RFA) for uterine fibroids, review the cur-
rent evidence base for the Sonata System, and offer a perspec-
tive on its potential role in the armamentarium of general and
specialized obstetrician-gynecologists who manage the many
women with symptomatic uterine leiomyomata.
Transcervical Radiofrequency Ablation of Uterine
Fibroids
As a hyperthermic energy source, radiofrequency energy heats
soft tissue to effect coagulative necrosis. The zone of
coagulative necrosis undergoes granulation and other inflam-
matory responses, resulting in fibrosis and volume reduction.
While radiofrequency ablation of uterine fibroids dates to
the early 1990s, these earlier efforts did not involve concurrent
imaging in order to match the volume of ablated tissue to that
of the targeted fibroid nor was the energy delivered
transcervically [11–14]. The use of concurrent sonography
has enabled a volumetric approach to RFA, which allows the
operator to minimize the number of ablations necessary to
ablate most or all of the targeted fibroid. And while earlier
devices for radiofrequency ablation required either laparoto-
my or laparoscopy, sonographic guidance has enabled a
transcervical approach, obviating the need for surgical inci-
sions [15–20].
Unlike the situation with malignancies, it is not necessary
to ablate 100% or more of a fibroid’s volume to provide
sustained clinical benefit [21]. Nonetheless, it is preferable
to ablate as much of a fibroid as is safely possible, as early
clinical evidence suggests a higher efficacy with increasing
percentages of ablated fibroid volume [21–23]. Furthermore,
fibroids that have been sufficiently ablated are rendered large-
ly or entirely necrotic, and while some tissue may remain in
situ, patients can realize symptom relief. When thermal energy
is delivered transcervically, it is important to ensure that heat is
not transferred to the uterine serosa and beyond, as that may
be adhesiogenic and risk thermal injury to adjacent organs
such as the bowel and the bladder. Graphical guidance sys-
tems can be helpful, both to assist with fibroid targeting and to
deliver energy within the serosal margin [24].
Overview of the Sonata System
The Sonata System consists of a reusable intrauterine ultra-
sound (IUUS) probe and a single-use disposable RFA
handpiece with proprietary Graphical Guidance Software
(GGS) for diagnosis and targeting. These components are in-
tegrated to provide the gynecologist with a real-time image-
guided treatment system.
The IUUS probe is used to identify fibroids fromwithin the
uterine cavity and guide deployment of an introducer and
needle electrodes into one or more targeted fibroids. The in-
trauterine sonography image offers a unique high-resolution
perspective of the uterus and nearby structures, including the
bowel, the bladder, and the adnexae. The IUUS probe image is
curvilinear, penetrates more than 9 cm, has a transmit frequen-
cy of 4.8–9.0 Mhz, and provides a 90° field of view. In con-
ventional transvaginal sonography, the endometrial stripe is a
useful landmark. But with intrauterine sonography, the IUUS
probe resides within the endometrial cavity proper. The imag-
ing plane is always directed at a 90° sector to the sonography
probe, so there is a single imaging plane rather than the sagittal
and coronal planes that make transvaginal sonography per-
haps more challenging.
The RFA handpiece is a single-use component that con-
tains an introducer and needle electrode array. The RFA
handpiece snaps together with the IUUS probe to form and
integrate into a single treatment device (Fig. 1) that contains
all the controls for the physician to place and size the ablation.
Mechanical stops and lockouts within the RFA handpiece
provide definitive Mechanical stops and lockouts within the
RFA handpiece provide definitive physical endpoints,
Fig. 1 The Sonata treatment device (combination of IUUS probe and
RFA handpiece)
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ensuring the ablation is properly located and sized as selected
by the physician using the included graphical software.
The Sonata Graphical Guidance Software, also known as
the SMART Guide™, is a real-time graphical overlay on the
ultrasound display. The SMART Guide allows the operating
gynecologist to visually select the deployment length, width,
and position of the ablation guides (thus setting the mechani-
cal stops for the introducer and needle electrodes) before any
hardware has been inserted into the fibroid target. By
displaying the ellipsoidal region where the ablation will take
place (ablation zone), along with a surrounding ellipsoid (ther-
mal safety border) where tissue temperatures will be elevated,
the SMART Guide may provide a safer and more accurate
fibroid ablation. These ellipsoidal guides were validated in
more than 4000 ablations in bovine muscle and human extir-
pated uteri, both ex vivo, as well as in vivo during laparotomy
(during early preclinical testing in which serosal temperatures
were monitored with direct placement of thermocouples and
concurrent infrared camera measurements of surface
temperatures).
Sonographically, the serosa appears as a hyperechoic struc-
ture. By using the SMART Guide, an ablation is positioned in
order to encompass as much of the fibroid as possible while
keeping thermal energy within the uterine serosal margin
(Fig. 2). Once the desired ablation size is selected and safe
placement of the needle electrodes is confirmed by rotating
the IUUS probe in multiple planes, therapeutic RF energy is
delivered to the fibroid according to a fixed treatment cycle
that is dependent on ablation size. The system is designed to
modulate power (up to 150 W) to keep temperatures at the
needle electrode tips around 105 °C, and the time at tempera-
ture (2–7 min) is automatically set based on the ablation size
that the gynecologist has selected via the SMART Guide. The
Sonata System can create a continuous range of ablation sizes
up to 4.0 cm wide and up to 5.0 cm long. Multiple ablations
may be created within a single fibroid.
Unlike operative hysteroscopy or transcervical fibroid
morcellation, only a small amount of hypotonic solution is
instilled within the endometrial cavity. This is performed for
acoustic coupling of the IUUS probe rather than for significant
uterine distension. The diameter of the treatment device,
which is comprised of both the IUUS probe and RFA
handpiece attached to one another, is 8.3 mm, compatible with
a cervical dilatation of 27 French.
The Sonata System, with its IUUS probe coupled to anoth-
er device (in this case, a RFA handpiece), forms a platform in
which other potential devices may be attached to the IUUS
probe and provide additional functionality beyond ablation.
Clinical Evidence
There is a growing evidence base relative to transcervical,
intrauterine sonography-guided RFA of fibroids with the
Sonata System.
Fig. 2 Transcervical RF ablation
with the Sonata System,
demonstrating the SMART Guide
that delineates the ablation zone
(red ellipsoid) and thermal safety
border (green ellipsoid. Note
explanation for each panel within
the Figure)
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Ablation Data After Immediate and Delayed
Hysterectomy
A single-site cohort study was performed involving 19 wom-
en (20 fibroids) undergoing either immediate (n = 12) or de-
layed (n = 7) hysterectomy after transcervical RF ablation with
the VizAblate System (as Sonata was formerly known) [24].
The study was intended to demonstrate the ability of the de-
vice to ablate the majority of fibroid volume in fibroids up to
5.0 cm in diameter while avoiding the uterine serosa.
Hysterectomies were performed via laparotomy in all cases,
with the delayed cohort having their hysterectomies 2 weeks
after transcervical RF fibroid ablation. All patients in the de-
layed hysterectomy group received conscious sedation during
their transcervical ablation procedures, whereas those in the
immediate hysterectomy group were managed with epidural
anesthesia. Ablation percentages in ablated fibroids were
ascertained after hysterectomy by staining the extirpated uteri
with the viability stain triphenyltetrazolium chloride (TTC) to
quantify fibroid ablation dimensions and assess the serosa for
thermal injury. There were 17 fibroids ≤5.0 cm in diameter
among the 19 patients, in which a median 75% of fibroid
volume was ablated (mean 67.2 ± 27.0%; range 15–100%).
No uteri were found on either gross visualization at hysterec-
tomy or upon histopathologic evaluation to have evidence for
uterine serosal injury.
European Clinical Trial Data: the Fibroid Ablation
Study-EU Trial
The Fibroid Ablation Study-EU (FAST-EU) Trial was a mul-
ticenter, prospective trial in the Netherlands, the UK, and
Mexico, that examined the clinical effects of the VizAblate
System in a cohort of women with symptomatic fibroids
[15, 16]. Each patient served as her own control, and an inde-
pendent core imaging laboratory was used to ensure quality
control and standardized interpretation of baseline and post-
ablation magnetic resonance images (MRI). Patients had to
have up to five treatable fibroids from 1 to 5 cm in diameter,
not desire future fertility, and were excluded for the presence
of type 0 myomata, ovulatory dysfunction, coagulopathy, and
adenomyosis. All patients had to have at least one fibroid that
indented the endometrial cavity (FIGO types 1 and 2), a men-
strual pictogram (MP) score of at least 120 and a baseline
score of 20 or greater on the Symptom Severity Score (SSS)
subscale of the Uterine Fibroid Symptom-Quality of Life
(UFS-QOL) questionnaire. Anesthesia was per physician
and patient choice.
The primary endpoint of the FAST-EU trial was the per-
centage change in perfused volume of ablated fibroids at
3 months as determined by contrast-enhanced MRI.
Reduction in perfused fibroid volume is a representation of
how much of the ablated fibroid is devascularized after abla-
tion and is believed to correlate with treatment success and
durability of symptom improvement [21]. Other endpoints,
which were reached at 6 months, included reduction in the
MP score (which represents the degree of menstrual blood
loss), overall safety, improvements in the SSS and health-re-
lated quality of life (HRQOL) subscales of the UFS-QOL,
patient satisfaction, anesthesia regimen, and recovery pain.
A total of 50 women (92 fibroids) were treated with
transcervical RFA under intrauterine sonography guidance.
All patients had undergone baseline transvaginal sonography,
hysteroscopy, or hysterosonography, as well as contrast-
enhanced MRI. Of the 92 fibroids treated, 56 (60.9%) were
either a type 1 (n = 14) or a type 2 (n = 42) fibroid, which is
consistent with the trial inclusion requirement for the presence
of at least one indenting myoma. Ablated fibroid diameters, as
determined by baseline MRI, ranged from 1.1–6.9 cm.
At 3 months, there was a 76.9% median reduction in per-
fused fibroid volume and a 62.5% median decrease in mean
total fibroid volume (P < 0.001). By 12 months, among 28
patients who provided their consent, contrast-enhance MRI
revealed a 73.3%median reduction in perfused fibroid volume
and a 73.3% median reduction in total fibroid volume
(P < 0.001).
With regard to menstrual bleeding, by 3 months, 89.8% of
patients reported a reduction in menstrual bleeding, with the
mean MP score decreasing consistently through 12 months
(Table 1). Lukes and colleagues have determined that a reduc-
tion in menstrual bleeding ≥22% is considered to be clinically
meaningful to women with abnormal uterine bleeding [25]. In
the FAST-EU trial, most patients (57.1–72.9%, based on the
time point) realized more than a 50% reduction in their MP
scores during the study, while 75.5% of patients achieved a
clinically meaningful reduction in their MP scores by
3 months. Similarly, there were significant improvements
(all P < 0.001 from baseline) in the SSS and HRQOL sub-
scales through 12 months (Table 1). A 10-point reduction in
SSS is considered to represent a moderate effect size [26].
Patients in the FAST-EU trial realized a mean 35.3-point re-
duction in their SSS scores at 12months, with as many as 86%
Table 1 Median percentage improvement in patient-reported outcomes
from baseline
3 months (%) 6 months (%) 12 months (%)
MP 56.9 68.6 72.3
SSS 52.5 66.7 62.5
HRQOL 123 118 127
MPmenstrual pictogram, SSS Symptom Severity Score,HRQOLHealth-
related Quality of Life (the last two are subscales of the Uterine Fibroid
Symptom-Quality of Life questionnaire)
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of patients at a single time point achieving at least a 10-point
reduction.
Patients returned to normal activity in a median 4.0 days
(mean 4.4 ± 3.1 days) and there was an overall satisfaction rate
of 87.8%. Two patients were admitted overnight for observa-
tion, one with lower abdominal pain believed secondary to
cystitis and the other for bradycardia after treatment received
under general anesthesia. The most frequent adverse events
consisted of dysmenorrhea (12%), abnormal uterine bleeding
above baseline (12%), pelvic pain/cramping (8%), and cystitis
(4%). One patient had a fibroid expulsion that was free of
sequelae. Four patients underwent elective reintervention be-
tween 7 and 12 months post-ablation, two with hysteroscopic
myomectomy, one with balloon thermal endometrial ablation,
and one with total abdominal hysterectomy.
There was a single pregnancy, which was diagnosed
6 months after ablation when the patient presented with
3 months of amenorrhea [27]. This resulted in a live-born
singleton pregnancy delivered by elective repeat Cesarean
section at term, with an uncomplicated perinatal course.
Future Research Efforts
The Sonata System is currently being evaluated as part of
an FDA-approved investigational device exemption (IDE)
trial (SONATA: Sonography-Guided Transcervical
Ablat ion of Uterine Fibroids; ClinicalTrials.gov
Identifier: NCT02228174) involving clinical sites in the
USA, Mexico, and Europe [28]. This trial aims to show
the safety and efficacy of transcervical RFA of uterine
fibroids associated with heavy menstrual bleeding.
As noted, successful pregnancy after treatment with the
Sonata System (formerly VizAblate) has been reported.
There is a growing evidence base concerning the potential
for women who have undergone hyperthermic ablation
with either focused ultrasound, microwaves, or radiofre-
quency energy to experience normal fertility and fecundi-
ty [20, 27, 29–36]. Nonetheless, radiofrequency ablation
of uterine fibroids in women who desire fertility remains
investigational in the USA, although treatment in women
desiring pregnancy has been approved by the US Food
and Drug Administration in the case of MR-guided fo-
cused ultrasound (MRgFUS), another hyperthermic abla-
tion modality. In order to examine whether transcervical
RFA of uterine fibroids with the Sonata System conserves
the structure of the myometrium, baseline and 12-month
post-ablation MR images will be examined as part of the
ongoing pivotal trial with regard to myometrial thickness
and integrity. Additional clinical trials are planned to pro-
vide further evidence regarding the role, if any, of
transcervical RF ablation in women who desire fecundity.
Discussion and Perspective
While hysterectomy and other more invasive options remain
prevalent, there remains a need for less invasive fibroid ther-
apy that is incisionless, preserves the uterus, and can treat
fibroids that are not limited to the narrow range of fibroid
types (FIGO types 0 and 1 and smaller type 2 fibroids) ame-
nable to transcervical treatment with a hysteroscope. It is
established that hysteroscopic management of type 2 fibroids
may be particularly challenging; hysteroscopic resection of
type 2 fibroids may have a 50% probability of requiring at
least one additional attempt at complete removal [37, 38].
The Sonata System, because it has an integrated intrauter-
ine sonography probe, is not limited to submucous fibroids
visible with hysteroscopic methods. The only fibroids that
would not be ablated with Sonata are pedunculated, namely
FIGO type 0 and type 7 myomata. Ablation of a type 7 fibroid
(pedunculated subserous myoma) would require ablation out-
side of the uterine serosa. Type 0 (intracavitary/pedunculated
submucous) myomata are generally amenable to hysteroscop-
ic resection [39, 40]. Unlike uterine artery embolization of
submucous myomata, which is more commonly associated
with bulk fibroid expulsion, hyperthermic ablation technolo-
gies such as MRgFUS and RFA tend to result in a gradual
sloughing of fibroid tissue from the endometrial cavity, with
bulk expulsion being much less common [16, 39, 41].
Because the imaging and treatment components of the
Sonata System are integrated into a single handheld device,
the operator only manages one device and one image, rather
than coordinate multiple devices (e.g., laparoscope, RF de-
vice, sonography probe) and images (video, sonography).
Intrauterine sonography provides a different imaging perspec-
tive from that of transvaginal sonography. As the curvilinear
IUUS probe always maintains the same relationship to the
portion of the uterus being imaged (i.e., there are no separate
coronal and sagittal planes depending on how the sonography
probe is angled), the imaging plane remains consistent while
scanning the entire circumference of the uterus. The uterine
serosa is an important landmark, appearing as a hyperechoic
border, and demarcates the limit beyond which the SMART
Guide’s thermal safety border must not pass.
The unique perspective and high-resolution imaging
afforded by the IUUS probe enables precise targeting and
RF ablation of a wide range of fibroid types, while the
SMART Guide provides a real-time visual display (ablation
zone) of where the ablation will occur along with the con-
straint of the thermal safety border. Because the mechanical
stops within the RFA handpiece limit needle electrode deploy-
ment based on the ablation size graphically chosen by the
operator, no manual measurements are needed to ascertain
where the needle electrodes should be deployed. The system
automatically calculates the time at temperature (105 °C)
based on the chosen ablation size and will stop the delivery
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of RF energy when the necessary time at temperature has
elapsed (2–7 min).
Radiofrequency ablation of uterine fibroids with the Sonata
System is a promising treatment approach that is currently
investigational in the USA and available under CE mark in
Europe. As a transcervically delivered fibroid treatment, the
uterine serosa is not compromised. Unlike hysteroscopic re-
section, tissue is not morcellated nor is significant and
prolonged uterine distention necessary. There is evidence in
the literature for ablation of fibroids up to 6.9 cm with the
Sonata System, and fibroids larger than 5.0 cm (the maximum
deployment length of the needle electrodes) may be
approached with multiple ablations [10, 16]. Neoadjuvant
treatment with gonadotropin-releasing hormone agonists or
selective progesterone receptor modulators, which medically
reduce fibroid volume, may be a complementary approach to
enable the optimal ablation of larger fibroids.
In an era in which physicians are increasingly performing
more invasive hysterectomies and myomectomies in the wake
of the US Food and Drug Administration guidance regarding
laparoscopic power morcellation, it is important that women
continue to have options for uterine fibroid therapy that are
less invasive and preserve their choices with regard to uterine
conservation [42]. The Sonata System, by virtue of being a
transcervical procedure that has a wider range of treatable
fibroid types than existing transcervical options, could signif-
icantly change the current paradigm in which women either
lose their uteri or potentially undergo surgical and radiologic
procedures that have significant drawbacks in terms of inva-
siveness and recovery time or require multiple treatment
sessions.
Conclusions
Because it is incisionless, does not require general anesthesia,
can ablate most types of uterine fibroids, and preserves the
uterus, the Sonata System represents an exciting new technol-
ogy for the treatment of uterine fibroids. This has been sup-
ported to date by the results of the FAST-EU trial in Europe
and Mexico, in which there were significant reductions in
fibroid volume and fibroid-associated symptoms. The ongo-
ing pivotal IDE trial (SONATA) will provide further evidence
regarding clinical outcomes and safety in a mostly US-based
patient cohort.
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